BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 20678016)

  • 1. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
    Pace F; Pace M
    Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness.
    Cho YK; Choi MG; Lim CH; Nam KW; Chang JH; Park JM; Lee IS; Kim SW; Choi KY; Chung IS
    Scand J Gastroenterol; 2010 May; 45(5):533-9. PubMed ID: 20180645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
    Lee KJ; Kwon HC; Cheong JY; Cho SW
    Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?
    Tack J; Koek G; Demedts I; Sifrim D; Janssens J
    Am J Gastroenterol; 2004 Jun; 99(6):981-8. PubMed ID: 15180713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-hour ambulatory pH-metry in patients with refractory heartburn: a prospective study.
    Talaie R; Forootan M; Donboli K; Dadashzadeh N; Sadeghi A; Poorsaadat S; Moghimi B; Mohammad Alizadeh AH; Zali MR
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):11-5. PubMed ID: 19337627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonerosive reflux disease.
    Long JD; Orlando RC
    Minerva Gastroenterol Dietol; 2007 Jun; 53(2):127-41. PubMed ID: 17557041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
    Watson TJ; Peters JH
    Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nonerosive reflux disease-gastroesophageal reflux disease controversy.
    Winter JW; Heading RC
    Curr Opin Gastroenterol; 2008 Jul; 24(4):509-15. PubMed ID: 18622168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
    Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
    Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD).
    Milkes D; Gerson LB; Triadafilopoulos G
    Am J Gastroenterol; 2004 Jun; 99(6):991-6. PubMed ID: 15180715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration.
    de Leone A; Tonini M; Dominici P; Grossi E; Pace F;
    Dig Liver Dis; 2010 Nov; 42(11):785-90. PubMed ID: 20452300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients.
    Kim JH; Sinn DH; Son HJ; Kim JJ; Rhee JC; Rhee PL
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1504-9. PubMed ID: 19467139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precise role of acid in non-erosive reflux disease.
    Wang C; Hunt RH
    Digestion; 2008; 78 Suppl 1():31-41. PubMed ID: 18832838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional heartburn and non-erosive reflux disease.
    Savarino V; Savarino E; Parodi A; Dulbecco P
    Dig Dis; 2007; 25(3):172-4. PubMed ID: 17827934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment.
    Poh CH; Gasiorowska A; Navarro-Rodriguez T; Willis MR; Hargadon D; Noelck N; Mohler J; Wendel CS; Fass R
    Gastrointest Endosc; 2010 Jan; 71(1):28-34. PubMed ID: 19922918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD).
    Papa A; Urgesi R; Grillo A; Danese S; Guglielmo S; Roberto I; Fedeli G; Gasbarrini A; Gasbarrini G
    Minerva Gastroenterol Dietol; 2004 Sep; 50(3):215-26. PubMed ID: 15729197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.